Company releases


Company releases

18/1/2022 Nightingale introduces combination of its proprietary blood test and genomics: acquires Finnish genetic testing company Negen and launches international centre of excellence for genomic data analysis

2/11/2021 Tuukka Paavola appointed as Chief Financial Officer of Nightingale Health Plc

29/10/2021 Conversion of Nightingale Health Plc’s Series A shares and EMP shares to Series B shares

28/10/2021 Resolutions of Nightingale Health Plc’s Annual General Meeting and Board of Directors

27/10/2021 Nightingale and major Finnish pharmacy chain Yliopiston Apteekki enter into nation-wide distribution partnership of Nightingale's at-home testing solution

13/10/2021 Nightingale and Terveystalo launch a new well-being membership

1/10/2021 Notice to the Annual General Meeting of Nightingale Health Plc

1/10/2021 Nightingale's Annual Report for financial year 2020–2021 published

15/9/2021 Nightingale Health Plc Financial Statements Release 1 July 2020 – 30 June 2021

30/8/2021 Jeffrey Barrett appointed as Chief Scientific Officer of Nightingale Health Plc

9/7/2021 Nightingale Health acquires German digital health company Yolife GmbH

1/7/2021 Nightingale Health quarterly summary of achieved key milestones and reiteration of near-term business targets

29/6/2021 Nightingale secures global scalability of its at-home solution by partnering with at-home blood collection device manufacturer Weavr with new commercial terms and minority investment

23/6/2021 Nightingale successfully completes the first phase of its at-home blood testing pilot

4/5/2021 Nightingale restructures its Management Team and established strategic partnership with Reaktor

29/4/2021 Nightingale Health signed service agreement for health and well-being services in Japan

22/4/2021 Nightingale Health Plc and Terveystalo have entered into strategic partnership agreement

9/4/2021 Nightingale Health Plc’s subsidiary received clinical laboratory certification in Japan

31/3/2021 The cancellation of Nightingale Health Plc’s treasury shares entered in the Trade Register

25/3/2021 Nightingale Health Plc’s ten largest shareholders after the completion of the initial public offering

23/3/2021 Stabilisation measures taken and the end of the stabilisation period; the Board of Directors has resolved on the cancellation of treasury shares

18/3/2021 The IPO of Nightingale has been oversubscribed and the listing will be completed as planned – trading in the series B shares is expected to commence on 19 March 2021

16/3/2021 Public offering of Nightingale has been oversubscribed and therefore the subscription period has been discontinued

15/3/2021 Nightingale Health Plc comments on the media coverage on its initial public offering

8/3/2021 Nightingale announces a fixed subscription price and publishes a prospectus for its contemplated IPO and listing of its series B shares on Nasdaq First North Growth Market Finland

8/3/2021 Nightingale has applied for its series B shares to be listed on Nasdaq First North Growth Market Finland and commences the initial public offering